Phase 4 Lung Cancer Trial, Recruiting NCT05463913 Sponsor: University Medical Center Groningen Condition: Lung Cancer
Back to Lung Cancer

Phase 4 Lung Cancer Trial, Recruiting

NCT05463913
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand and agree to take part in the trial and have signed a consent form
  • People who have one or more lung nodules of a specific size (6–15 mm) that have been found on a CT chest scan and have not yet been clearly identified as cancerous or non-cancerous
  • People who have already had a routine PET/CT scan using a substance called 18F-FDG (a type of imaging scan)
  • People who are already scheduled to have a biopsy or surgical removal of their lung nodule(s)

Who may not be able to join:

  • People who experience severe anxiety or fear in enclosed spaces (claustrophobia)
  • People who are pregnant or currently breastfeeding
  • People who have received systemic anti-cancer treatment (such as chemotherapy) within the last 2 weeks before their PET scan
  • People who have had radiation therapy directed at the lung nodule(s) being studied
  • People who have diabetes that is not well controlled
  • People who have any other medical condition that could interfere with taking part in the trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Adrienne H Brouwers, MD PhD, Nuclear Medicine physician

Phone: +31503613093

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
13 July 2022
Est. completion
1 June 2025

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Description of optimized (in terms of e.g. activity dose needed for injection, time of scan duration, post-processing filtering) static whole-body acquisition and reconstruction protocol by performing semi-quantitative (SUV) analysis.; Description of optimized (in terms of e.g. activity dose needed for injection, time of scan duration) dynamic whole-body acquisition and reconstruction protocol by performing kinetic modelling (Patlak, Ki) analysis.; Description of optimized breath-hold acquisition and reconstruction protocol by performing semi-quantitative (SUV) analysis and compare with outcom...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov